Carlsmed Completes First Spine Surgery Using Aprevo System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy CARL?
Carlsmed announced the successful completion of the first posterior lumbar spine surgery using the Company's aprevo Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado. "This clinical milestone strengthens our position as a leader in personalized, data-driven spine solutions designed to help surgeons plan with greater precision, improve patient outcomes, and reduce costly revisions. The addition of the aprevo(R) Bi-lateral Posterior Lumbar Interbody Fusion procedure to our personalized surgery procedure portfolio further demonstrates the power and versatility of our personalized, AI-enabled approach to spine surgery," said Mike Cordonnier, Chairman and CEO of Carlsmed. "We look forward to our full commercial launch this year to provide this personalized procedural option to patients, surgeons, and hospital systems on a larger scale."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CARL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CARL
Wall Street analysts forecast CARL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.660
Low
18.00
Averages
20.50
High
24.00
Current: 9.660
Low
18.00
Averages
20.50
High
24.00
About CARL
Carlsmed, Inc. is a commercial-stage medical technology company providing AI-enabled personalized spine surgery solutions. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights intended to improve the digital surgical planning process. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Carlsmed Reports Q4 Earnings Beat with Strong Revenue Growth Outlook
- Earnings Beat: Carlsmed reported a Q4 GAAP EPS of -$0.32, surpassing expectations by $0.11, indicating positive progress in the company's recovery of profitability.
- Revenue Growth: The company achieved Q4 revenue of $15.2 million, exceeding market expectations by $0.34 million, reflecting strong product demand and an increase in market share.
- Future Outlook: Carlsmed targets revenue between $70 million and $75 million for 2026, with plans to launch cervical and bilateral products, demonstrating confidence in future growth.
- Growth Prospects: The company anticipates a 44% growth outlook, highlighting its competitiveness and ongoing innovation capabilities in the medical device market.
See More
Carlsmed, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Carlsmed reported $15.2 million in revenue for Q4 2025, a 61% increase from $9.4 million in Q4 2024, demonstrating strong expansion potential in the spine surgery market.
- Improved Gross Margins: The gross margin for Q4 reached 76.5%, up from 74.7% in Q4 2024, indicating substantial progress in cost control and operational efficiency.
- New Product Launches: The company announced the launch of the first bilateral posterior aprevo procedure, with a full commercial release planned for the second half of 2026, further enhancing market penetration for personalized spine surgery.
- Optimistic Future Outlook: The CFO projected 2026 revenue between $70 million and $75 million, representing a 44% annual growth rate at the midpoint, reflecting confidence in sustained growth and market demand.
See More
Carlsmed Reports 86% Revenue Growth in 2025 Financial Results
- Quarterly Revenue Growth: Carlsmed reported fourth-quarter revenue of $15.2 million, reflecting a 61.2% year-over-year increase, which underscores the strong market demand for its personalized spine surgery solutions and solidifies its position in the medical technology sector.
- Impressive Annual Performance: The company achieved full-year revenue of $50.5 million in 2025, an 86% increase compared to 2024, indicating effective scaling and profitability enhancement, likely to attract more investor interest.
- Gross Margin Improvement: The gross margin for the fourth quarter reached 76.5%, up from 74.7% in the previous year, demonstrating ongoing improvements in cost control and operational efficiency, which are crucial for enhancing market competitiveness.
- Optimistic Future Outlook: Carlsmed anticipates revenue for 2026 to range between $70 million and $75 million, representing a 44% growth at the midpoint compared to 2025, reflecting the company's confidence in future growth and its ongoing innovation in the medical technology field.
See More
Carlsmed Achieves Milestone in Personalized Cervical Plating Procedure
- Surgical Milestone: Carlsmed successfully performed the first personalized cervical plating procedure at UCSF, marking a significant advancement for its corra Cervical Plating System and boosting positive sentiment around its stock.
- Product Innovation: The corra system aims to enhance surgical precision and improve patient outcomes by utilizing patient-specific plates tailored to individual anatomical needs, with plans for further evaluations and a commercial launch later this year.
- Digital Surgery Ecosystem: Leveraging Carlsmed's digital surgery ecosystem, the system customizes key anatomical features, including screw positioning and plate curvature, pre-operatively for each vertebral level, supporting consistent fixation and precise alignment for ACDF procedures.
- Wall Street Optimism: Carlsmed's stock carries a Buy rating with an average price target of $20.25, with analysts from BTIG and Truist Securities raising their targets to $24.00 and $20.00 respectively, reflecting confidence in the company's future performance.
See More
Carlsmed to Report Q4 and Full Year 2025 Results on February 25
- Earnings Report Schedule: Carlsmed will release its Q4 and full year 2025 financial results after market close on February 25, 2026, providing investors with the latest insights into the company's operational performance.
- Conference Call Details: Management will host a conference call and webcast at 1:30 PM Pacific Time, with participants encouraged to dial in 5 to 10 minutes early to ensure they receive timely updates on company developments.
- Replay Availability: A replay of the webcast will be available shortly after the call concludes, allowing investors who could not attend live to review the meeting content, thereby enhancing information transparency.
- Company Mission: Carlsmed is committed to improving healthcare outcomes and reducing costs for spine surgery through AI-enabled personalized solutions, showcasing its innovative potential and competitive edge in the medical technology sector.
See More
Heineken Plans 7% Workforce Layoffs to Boost Efficiency
- Layoff Plan: Heineken plans to cut 5,000 to 6,000 jobs over the next two years, representing about 7% of its 87,000 workforce, aiming to enhance productivity in response to a 2.4% decline in beer sales last year.
- Profit Growth Target: Despite the drop in total beer volumes, Heineken's adjusted operating profit rose by 4.4%, with the company forecasting operating profit growth of 2% to 6% for 2026, demonstrating resilience in a challenging market environment.
- Digital Transformation: The layoffs are partly attributed to the push for AI and digitization, with around 3,000 roles expected to move to business services, aiming for annual savings of €400 to €500 million, further advancing its EverGreen 2030 strategy.
- Market Reaction: Heineken's shares rose 3.4% in the latest trading session, and the stock is up nearly 7% year-to-date, reflecting market confidence in its strategic adjustments and future growth potential.
See More
Carlsmed Reports Q4 Earnings Beat with Strong Revenue Growth Outlook
- Earnings Beat: Carlsmed reported a Q4 GAAP EPS of -$0.32, surpassing expectations by $0.11, indicating positive progress in the company's recovery of profitability.
- Revenue Growth: The company achieved Q4 revenue of $15.2 million, exceeding market expectations by $0.34 million, reflecting strong product demand and an increase in market share.
- Future Outlook: Carlsmed targets revenue between $70 million and $75 million for 2026, with plans to launch cervical and bilateral products, demonstrating confidence in future growth.
- Growth Prospects: The company anticipates a 44% growth outlook, highlighting its competitiveness and ongoing innovation capabilities in the medical device market.
See More
Carlsmed, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Revenue Growth: Carlsmed reported $15.2 million in revenue for Q4 2025, a 61% increase from $9.4 million in Q4 2024, demonstrating strong expansion potential in the spine surgery market.
- Improved Gross Margins: The gross margin for Q4 reached 76.5%, up from 74.7% in Q4 2024, indicating substantial progress in cost control and operational efficiency.
- New Product Launches: The company announced the launch of the first bilateral posterior aprevo procedure, with a full commercial release planned for the second half of 2026, further enhancing market penetration for personalized spine surgery.
- Optimistic Future Outlook: The CFO projected 2026 revenue between $70 million and $75 million, representing a 44% annual growth rate at the midpoint, reflecting confidence in sustained growth and market demand.
See More
Carlsmed Reports 86% Revenue Growth in 2025 Financial Results
- Quarterly Revenue Growth: Carlsmed reported fourth-quarter revenue of $15.2 million, reflecting a 61.2% year-over-year increase, which underscores the strong market demand for its personalized spine surgery solutions and solidifies its position in the medical technology sector.
- Impressive Annual Performance: The company achieved full-year revenue of $50.5 million in 2025, an 86% increase compared to 2024, indicating effective scaling and profitability enhancement, likely to attract more investor interest.
- Gross Margin Improvement: The gross margin for the fourth quarter reached 76.5%, up from 74.7% in the previous year, demonstrating ongoing improvements in cost control and operational efficiency, which are crucial for enhancing market competitiveness.
- Optimistic Future Outlook: Carlsmed anticipates revenue for 2026 to range between $70 million and $75 million, representing a 44% growth at the midpoint compared to 2025, reflecting the company's confidence in future growth and its ongoing innovation in the medical technology field.
See More
Carlsmed Achieves Milestone in Personalized Cervical Plating Procedure
- Surgical Milestone: Carlsmed successfully performed the first personalized cervical plating procedure at UCSF, marking a significant advancement for its corra Cervical Plating System and boosting positive sentiment around its stock.
- Product Innovation: The corra system aims to enhance surgical precision and improve patient outcomes by utilizing patient-specific plates tailored to individual anatomical needs, with plans for further evaluations and a commercial launch later this year.
- Digital Surgery Ecosystem: Leveraging Carlsmed's digital surgery ecosystem, the system customizes key anatomical features, including screw positioning and plate curvature, pre-operatively for each vertebral level, supporting consistent fixation and precise alignment for ACDF procedures.
- Wall Street Optimism: Carlsmed's stock carries a Buy rating with an average price target of $20.25, with analysts from BTIG and Truist Securities raising their targets to $24.00 and $20.00 respectively, reflecting confidence in the company's future performance.
See More
Carlsmed to Report Q4 and Full Year 2025 Results on February 25
- Earnings Report Schedule: Carlsmed will release its Q4 and full year 2025 financial results after market close on February 25, 2026, providing investors with the latest insights into the company's operational performance.
- Conference Call Details: Management will host a conference call and webcast at 1:30 PM Pacific Time, with participants encouraged to dial in 5 to 10 minutes early to ensure they receive timely updates on company developments.
- Replay Availability: A replay of the webcast will be available shortly after the call concludes, allowing investors who could not attend live to review the meeting content, thereby enhancing information transparency.
- Company Mission: Carlsmed is committed to improving healthcare outcomes and reducing costs for spine surgery through AI-enabled personalized solutions, showcasing its innovative potential and competitive edge in the medical technology sector.
See More
Heineken Plans 7% Workforce Layoffs to Boost Efficiency
- Layoff Plan: Heineken plans to cut 5,000 to 6,000 jobs over the next two years, representing about 7% of its 87,000 workforce, aiming to enhance productivity in response to a 2.4% decline in beer sales last year.
- Profit Growth Target: Despite the drop in total beer volumes, Heineken's adjusted operating profit rose by 4.4%, with the company forecasting operating profit growth of 2% to 6% for 2026, demonstrating resilience in a challenging market environment.
- Digital Transformation: The layoffs are partly attributed to the push for AI and digitization, with around 3,000 roles expected to move to business services, aiming for annual savings of €400 to €500 million, further advancing its EverGreen 2030 strategy.
- Market Reaction: Heineken's shares rose 3.4% in the latest trading session, and the stock is up nearly 7% year-to-date, reflecting market confidence in its strategic adjustments and future growth potential.
See More
